- Home
- EDBL vs INM Comparison
EDBL vs INM Comparison
Compare EDBL & INM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EDBL
- INM
- Stock Information
- Founded
- EDBL 2020
- INM 1981
- Country
- EDBL United States
- INM Canada
- Employees
- EDBL N/A
- INM N/A
- Industry
- EDBL Farming/Seeds/Milling
- INM Biotechnology: Pharmaceutical Preparations
- Sector
- EDBL Consumer Staples
- INM Health Care
- Exchange
- EDBL Nasdaq
- INM Nasdaq
- Market Cap
- EDBL 5.4M
- INM 5.0M
- IPO Year
- EDBL 2022
- INM N/A
- Fundamental
- Price
- EDBL $1.62
- INM $2.00
- Analyst Decision
- EDBL
- INM
- Analyst Count
- EDBL 0
- INM 0
- Target Price
- EDBL N/A
- INM N/A
- AVG Volume (30 Days)
- EDBL 506.2K
- INM 102.6K
- Earning Date
- EDBL 11-12-2025
- INM 11-13-2025
- Dividend Yield
- EDBL N/A
- INM N/A
- EPS Growth
- EDBL N/A
- INM N/A
- EPS
- EDBL N/A
- INM N/A
- Revenue
- EDBL $12,320,000.00
- INM $4,942,633.00
- Revenue This Year
- EDBL $29.56
- INM N/A
- Revenue Next Year
- EDBL $20.00
- INM N/A
- P/E Ratio
- EDBL N/A
- INM N/A
- Revenue Growth
- EDBL N/A
- INM 7.50
- 52 Week Low
- EDBL $1.52
- INM $1.72
- 52 Week High
- EDBL $13.50
- INM $8.27
- Technical
- Relative Strength Index (RSI)
- EDBL 39.27
- INM 38.56
- Support Level
- EDBL $1.59
- INM $2.04
- Resistance Level
- EDBL $2.78
- INM $2.14
- Average True Range (ATR)
- EDBL 0.20
- INM 0.12
- MACD
- EDBL -0.03
- INM -0.02
- Stochastic Oscillator
- EDBL 7.93
- INM 0.00
About EDBL Edible Garden AG Incorporated
Edible Garden AG Inc is a next-generation controlled environment agriculture farming company. It uses traditional agricultural growing techniques together with technology to grow fresh, organic food, sustainably and safely while improving traceability. The company uses the controlled environment of traditional greenhouse structures, such as glass greenhouses together with hydroponic and vertical greenhouses to sustainably grow organic herbs and lettuces.
About INM InMed Pharmaceuticals Inc.
InMed Pharmaceuticals Inc is a Canada based clinical-stage biopharmaceutical company. The Company's operations consist of two operating and reportable segments, the InMed Pharma segment and the BayMedica Commercial segment. The InMed Pharma segment is largely organized around the research and development of small molecule pharmaceuticals drug candidates and the BayMedica Commercial segment is largely organized around manufacturing technologies to produce and commercialize bulk rare cannabinoids for sale as ingredients in the health and wellness industry. Its product portfolio includes INM-755, which is used for the treatment of epidermolysis bullosa; INM-088 for the treatment of glaucoma; INM-901 for Alzheimer's disease.